Phase I/II clinical trial - Pédiatrie Tumeurs solides
D419EC00001
Pédiatrie Tumeurs solides
Essai clinique fermé
Public cible
Enfant
Phase I/II, open-label, multicentre study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumours, haematological malignancies including lymphoma and acute leukaemias
Description de l'essai
This is a multicentre, open-label, dose-finding and dose-expansion study to evaluate the safety, tolerability, PK, immunogenicity, and preliminary anti-tumor activity of Investigational Product 1 (IP1 - a PD-L1 inhibitor) monotherapy or IP1 in combination with Investigational Product 2 (IP2 - a CTLA-4 inhibitor) in paediatric patients with advanced solid tumors and hematological malignancies including lymphoma and acute leukemia, who have explored all approved therapies
Liens utiles
FRANCOIS DOZ
Investigateur principal